Cargando…
Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination
The rVSV-ZEBOV Ebolavirus vaccine confers protection within days after immunization, suggesting the contribution of innate immune responses. We report modulation of rVSV-ZEBOV vaccinee blood CD56(+) NK cell numbers, NKG2D or NKp30 surface receptor expression, Killer Immunoglobulin-like Receptor (KIR...
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156503/ https://www.ncbi.nlm.nih.gov/pubmed/32337075 http://dx.doi.org/10.1038/s41541-020-0179-4 |
| _version_ | 1783522221758611456 |
|---|---|
| author | Pejoski, David de Rham, Casimir Martinez-Murillo, Paola Santoro, Francesco Auderset, Floriane Medaglini, Donata Pozzi, Gianni Vono, Maria Lambert, Paul-Henri Huttner, Angela Haks, Mariëlle C. Ottenhoff, Tom H. M. Villard, Jean Siegrist, Claire-Anne |
| author_facet | Pejoski, David de Rham, Casimir Martinez-Murillo, Paola Santoro, Francesco Auderset, Floriane Medaglini, Donata Pozzi, Gianni Vono, Maria Lambert, Paul-Henri Huttner, Angela Haks, Mariëlle C. Ottenhoff, Tom H. M. Villard, Jean Siegrist, Claire-Anne |
| author_sort | Pejoski, David |
| collection | PubMed |
| description | The rVSV-ZEBOV Ebolavirus vaccine confers protection within days after immunization, suggesting the contribution of innate immune responses. We report modulation of rVSV-ZEBOV vaccinee blood CD56(+) NK cell numbers, NKG2D or NKp30 surface receptor expression, Killer Immunoglobulin-like Receptor (KIR)(+) cell percentages and NK-cell-related genes on day 1 post immunization. Inverse correlations existed between the concentration of several plasma cytokines and inhibitory KIR(+) CD56(dim) or cytokine-responsive CD56(bright) NK cells. Thus, NK cells may contribute to the early protective efficacy of rVSV-ZEBOV in humans. |
| format | Online Article Text |
| id | pubmed-7156503 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-71565032020-04-24 Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination Pejoski, David de Rham, Casimir Martinez-Murillo, Paola Santoro, Francesco Auderset, Floriane Medaglini, Donata Pozzi, Gianni Vono, Maria Lambert, Paul-Henri Huttner, Angela Haks, Mariëlle C. Ottenhoff, Tom H. M. Villard, Jean Siegrist, Claire-Anne NPJ Vaccines Brief Communication The rVSV-ZEBOV Ebolavirus vaccine confers protection within days after immunization, suggesting the contribution of innate immune responses. We report modulation of rVSV-ZEBOV vaccinee blood CD56(+) NK cell numbers, NKG2D or NKp30 surface receptor expression, Killer Immunoglobulin-like Receptor (KIR)(+) cell percentages and NK-cell-related genes on day 1 post immunization. Inverse correlations existed between the concentration of several plasma cytokines and inhibitory KIR(+) CD56(dim) or cytokine-responsive CD56(bright) NK cells. Thus, NK cells may contribute to the early protective efficacy of rVSV-ZEBOV in humans. Nature Publishing Group UK 2020-04-14 /pmc/articles/PMC7156503/ /pubmed/32337075 http://dx.doi.org/10.1038/s41541-020-0179-4 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Brief Communication Pejoski, David de Rham, Casimir Martinez-Murillo, Paola Santoro, Francesco Auderset, Floriane Medaglini, Donata Pozzi, Gianni Vono, Maria Lambert, Paul-Henri Huttner, Angela Haks, Mariëlle C. Ottenhoff, Tom H. M. Villard, Jean Siegrist, Claire-Anne Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination |
| title | Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination |
| title_full | Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination |
| title_fullStr | Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination |
| title_full_unstemmed | Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination |
| title_short | Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination |
| title_sort | rapid dose-dependent natural killer (nk) cell modulation and cytokine responses following human rvsv-zebov ebolavirus vaccination |
| topic | Brief Communication |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156503/ https://www.ncbi.nlm.nih.gov/pubmed/32337075 http://dx.doi.org/10.1038/s41541-020-0179-4 |
| work_keys_str_mv | AT pejoskidavid rapiddosedependentnaturalkillernkcellmodulationandcytokineresponsesfollowinghumanrvsvzebovebolavirusvaccination AT derhamcasimir rapiddosedependentnaturalkillernkcellmodulationandcytokineresponsesfollowinghumanrvsvzebovebolavirusvaccination AT martinezmurillopaola rapiddosedependentnaturalkillernkcellmodulationandcytokineresponsesfollowinghumanrvsvzebovebolavirusvaccination AT santorofrancesco rapiddosedependentnaturalkillernkcellmodulationandcytokineresponsesfollowinghumanrvsvzebovebolavirusvaccination AT audersetfloriane rapiddosedependentnaturalkillernkcellmodulationandcytokineresponsesfollowinghumanrvsvzebovebolavirusvaccination AT medaglinidonata rapiddosedependentnaturalkillernkcellmodulationandcytokineresponsesfollowinghumanrvsvzebovebolavirusvaccination AT pozzigianni rapiddosedependentnaturalkillernkcellmodulationandcytokineresponsesfollowinghumanrvsvzebovebolavirusvaccination AT vonomaria rapiddosedependentnaturalkillernkcellmodulationandcytokineresponsesfollowinghumanrvsvzebovebolavirusvaccination AT lambertpaulhenri rapiddosedependentnaturalkillernkcellmodulationandcytokineresponsesfollowinghumanrvsvzebovebolavirusvaccination AT huttnerangela rapiddosedependentnaturalkillernkcellmodulationandcytokineresponsesfollowinghumanrvsvzebovebolavirusvaccination AT haksmariellec rapiddosedependentnaturalkillernkcellmodulationandcytokineresponsesfollowinghumanrvsvzebovebolavirusvaccination AT ottenhofftomhm rapiddosedependentnaturalkillernkcellmodulationandcytokineresponsesfollowinghumanrvsvzebovebolavirusvaccination AT villardjean rapiddosedependentnaturalkillernkcellmodulationandcytokineresponsesfollowinghumanrvsvzebovebolavirusvaccination AT siegristclaireanne rapiddosedependentnaturalkillernkcellmodulationandcytokineresponsesfollowinghumanrvsvzebovebolavirusvaccination AT rapiddosedependentnaturalkillernkcellmodulationandcytokineresponsesfollowinghumanrvsvzebovebolavirusvaccination AT rapiddosedependentnaturalkillernkcellmodulationandcytokineresponsesfollowinghumanrvsvzebovebolavirusvaccination AT rapiddosedependentnaturalkillernkcellmodulationandcytokineresponsesfollowinghumanrvsvzebovebolavirusvaccination |